ClinicalTrials.gg
RecruitingNCT03983473MICROSPAUpdated Jun 18, 2026

Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.

An interventional study of Microbiota Sequencing in Crohn Disease and Spondyloarthritis, sponsored by Central Hospital, Nancy, France. Recruiting at 2 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Crohn Disease by Central Hospital, Nancy, France — 6 open to participants now, 7 under way, none of them phase 3. Crohn Disease · Central Hospital, Nancy, France.

Planned enrollment
2nd of 10
240 · median 104
Started
2021
with 2 others
No phase
10 of 17
5 open now
Registered
6th of 17
by date

Among the 17 studies in Crohn Disease by Central Hospital, Nancy, France, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2021, is one of 10 with no phase, and was the 6th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 17 studies in Crohn Disease by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Crohn Disease by Central Hospital, Nancy, France, or all of them as a file.
02

Study summary

The MICROSPA project aims to compare gut microbiota, serum cytokines, and PBMC of patients suffering from Crohn's disease (CD) associated or not to spondylarthritis (SpA). 3 groups of patients will be analyzed: patients suffering from CD alone, patients suffering from SpA alone, patients suffering from CD and SpA. One group of healthy controls will be analysed as a comparator. Fecal microbiota will be determined by bacteriome, virome and fungome NGS sequencing

03

Conditions studied

  • Crohn Disease
  • Spondyloarthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Patients will be recruited according to 3 groups:
  • Patients with Crohn's disease and axial spondyloarthritis according to the criteria below.
  • Patients with Crohn's disease (MC patients) with a diagnosis established according to clinical, biological criteria, radiological, endoscopic and / or histological studies for 3 months. With diagnosis of exclusion of a spondyloarthritis on criteria ASAS and / or New York modified.
  • Patients with axial spondyloarthritis (SpA patients) with a diagnosis based on modified ASAS and / or New York criteria with exclusion diagnosis of Crohn's disease.
  • Patient with the ability to give free and express .

Exclusion criteria

Exclusion Criteria:

  • History of colonic resection
  • Taking antibiotics or colon preparation for colonoscopy within 8 weeks before stool collection (Temporary = removal possible before colic or first bowel preparation after the start of colonic preparation).
  • Ostomy at the time of sampling
  • > 30
  • extreme diet
  • unbalanced diabetes
  • Pregnant woman
  • Patient under guardianship, under curatorship or under the protection of justice Contacts/Locations Central Contact
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Other
    Crohn's disease

    Patients suffering from established Crohn 's disease without spondyloarthritis

    Other: Microbiota Sequencing

  • Other
    Spondyloarthritis

    Patients with established spondyloarthritis without Crohn 's disease

    Other: Microbiota Sequencing

  • Other
    Crohn + spondyloarthritis

    Patients suffering from both spondyloarthritis and Crohn 's disease

    Other: Microbiota Sequencing

  • Other
    Healthy controls

    Patients without spondyloarthritis and Crohn 's disease

    Other: Microbiota Sequencing

Interventions

  • OtherMicrobiota Sequencing

    virome, bacteriome, fungome NGS sequencing

06

What researchers measure

Primary outcomes

  1. Alpha and Beta diversity of Fecal bacteriome

    Alpha (number of species) and Beta diversity (distribution of species)

    Time frame: + 6 months

  2. Alpha and Beta diversity of Fecal fungome

    Alpha (number of species) and Beta diversity (distribution of species)

    Time frame: + 6 months

  3. Alpha and Beta diversity of Fecal virome

    Alpha (number of species) and Beta diversity (distribution of species)

    Time frame: + 6 months

07

Study locations

2 of 2 sites recruiting
  • Central Hospital
    Nancy, Lorraine 54500, France
    Recruiting
    • Laurent MD PEYRIN-BIROULET, PhD · Contact
  • Saint Antoine Hospital
    Paris, 75012, France
    Recruiting
    • Harry SOKOL, MD, PhD · Contact
    • Jérémie SELLAM, MD, PhD · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Nov 2027, 71 months after the start.

Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 71 months is above that.

Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2019
First posted
Jun 12, 2019
StartActual
Nov 16, 2021
Primary completionEst.
Nov 4, 2027
CompletionEst.
Dec 16, 2027
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03983473
Responsible party
FERRY Marine (Doctor, Central Hospital, Nancy, France) — Principal investigator
First posted
Jun 12, 2019
Start date
Nov 16, 2021
Primary completion
Nov 4, 2027 (estimated)
Completion
Dec 16, 2027 (estimated)
Last update
Jun 18, 2026

Study contacts

Laurent MD PEYRIN-BIROULET, PhD
Contact
peyrinbiroulet@gmail.com
0383153661

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion